HLS Therapeutics Inc.

HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 16, 2023.

A total of 28,831,784 Common Shares, or 89.12% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows:

Name of Nominee	Votes Cast FOR	% of Vote Cast FOR	Votes WITHHELD	% of Votes WITHHELD
Greg Gubitz	22,455,427	79.91	5,644,061	20.09
Rodney Hill	25,391,740	90.36	2,707,748	9.64
Laura Brege	23,482,483	83.57	4,617,005	16.43
John Welborn	27,129,959	96.55	969,529	3.45
Norma Beauchamp	23,498,085	83.63	4,601,403	16.38
Kyle Dempsey	26,205,959	93.26	1,893,529	6.74
Craig Millian	27,133,127	96.56	966,361	3.44
Christian Roy	27,145,091	96.60	954,397	3.40

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the Company's auditors with 28,796,380 votes (99.88%) cast "for" and 35,404 votes (0.12%) "withheld".

Shareholders also approved certain proposed amendments to the Corporation's Stock Option Plan, and approved the unallocated options thereunder, with 23,405,117 votes (83.29%) cast "for" and 4,694,371 votes (16.71%) cast "against".

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

For further information: HLS CONTACT INFORMATION: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, d.mason@hlstherapeutics.com

---

https://hlstherapeutics.investorroom.com/2023-06-16-HLS-Therapeutics-Reports-Annual-Meeting-Results